Measles-mumps-rubella vaccination timing and autism among young african american boys: a reanalysis of CDC data by Brian S Hooker
RESEARCH Open Access
Measles-mumps-rubella vaccination timing and
autism among young african american boys:
a reanalysis of CDC data
Brian S Hooker
A retraction article was published for this article. It is available from the following link; http://www.
translationalneurodegeneration.com/content/3/1/22
Abstract
Background: A significant number of children diagnosed with autism spectrum disorder suffer a loss of
previously-acquired skills, suggesting neurodegeneration or a type of progressive encephalopathy with an
etiological basis occurring after birth. The purpose of this study is to investigate the effectof the age at which
children got their first Measles-Mumps-Rubella (MMR) vaccine on autism incidence. This is a reanalysis of the
data set, obtained from the U.S. Centers for Disease Control and Protection (CDC), used for the Destefano et al.
2004 publication on the timing of the first MMR vaccine and autism diagnoses.
Methods: The author embarked on the present study to evaluate whether a relationship exists between child age
when the first MMR vaccine was administered among cases diagnosed with autism and controls born between
1986 through 1993 among school children in metropolitan Atlanta. The Pearson’s chi-squared method was used to
assess relative risks of receiving an autism diagnosis within the total cohort as well as among different race and
gender categories.
Results: When comparing cases and controls receiving their first MMR vaccine before and after 36 months of age,
there was a statistically significant increase in autism cases specifically among African American males who received
the first MMR prior to 36 months of age. Relative risks for males in general and African American males were 1.69
(p=0.0138) and 3.36 (p=0.0019), respectively. Additionally, African American males showed an odds ratio of 1.73
(p=0.0200) for autism cases in children receiving their first MMR vaccine prior to 24 months of age versus 24
months of age and thereafter.
Conclusions: The present study provides new epidemiologic evidence showing that African American males receiving
the MMR vaccine prior to 24 months of age or 36 months of age are more likely to receive an autism diagnosis.
Keywords: Autism, Measles-mumps-rubella (MMR) vaccine
Background
Autism is defined by persistent deficits in social communi-
cation and social interaction across multiple contexts and
restricted, repetitive patterns of behavior, interests, or ac-
tivities [1]. Autism incidence has risen dramatically over
the past two decades [2] and it has recently been reported
that one in sixty-eight children have this disorder [3]. In
addition to these core deficits, autism has also been char-
acterized by many other comorbid conditions including
gastrointestinal issues, sleep issues, eating disorders and
sensory processing issues [4].
It has been estimated that as many as 62% of children
with autism experience a period of regression during early
childhood, characterized by loss of previously acquired
skills [5]. This period has been reported as ranging be-
tween 6 and 36 months of age with the typical age of re-
gression between 18 and 24 months [6]. This period of
regression occurs within the same time period that chil-
dren in the United States typically receive their required
vaccinations and thus there have been many studiesCorrespondence: bhooker@simpsonu.edu
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regarding the incidence of autism and the receipt of spe-
cific vaccines. One of the primary concerns has been the
timing of the administration of the first measles-mumps-
rubella (MMR) vaccine.
The relationship between the MMR vaccine and autism
was first hypothesized by Wakefield et al. [7] in 1999 after
the observation of a regressive phenotype of autism that ap-
peared in general after the administration of the first MMR
vaccine. Although several studies have affirmed such a rela-
tionship between the MMR vaccine and neurodevelopmen-
tal disorders including autism [8,9], many other studies
purport no statistical relationship between the MMR vac-
cine and autism incidence. The latter studies have been per-
formed using cohorts from Denmark [10], Japan [11] and
Poland [12], as well as the MMR vaccine and pervasive de-
velopmental disorder in Canada [13]. In addition, in 2004,
Destefano et al. [14] published a paper describing a case–
control study completed on children, in metropolitan At-
lanta, who had been born between 1986 and 1993. Within
this study, the age at the first MMR vaccine was assessed as
a factor in the incidence of autism. Using conditional logis-
tic regression, with first MMR age as the independent vari-
able and autism incidence as the dependent variable, the
study authors assessed relative risk for obtaining an autism
diagnosis for those children receiving the first MMR vac-
cine before and after 18 months, 24 months and 36 months
of age. Destefano et al. [14] found a statistically significant
relative risk of 1.49 (95% confidence interval [CI]: 1.04 –
2.14) at the 36 month cut-off (i.e., in a comparison of
children receiving the MMR before versus after
36 months). Rather than concluding that the first MMR
vaccine could be playing a causal role in autism in these
children, the study authors instead attributed the in-
creased risk to greater numbers of autistic children re-
ceiving timely vaccinations in order to participate in
State of Georgia special education services.
In this paper, we present the results of a cohort study
using the same data from the Destefano et al. [14] ana-
lysis. The focus of the current study is differences in re-
sults in specific gender and race groups.
Methods
Cohort data
Cohort data were obtained directly as a “restricted access
data set” from the Centers for Disease Control and Preven-
tion (CDC) via a Data Use Agreement. Data were deidenti-
fied by the CDC in accordance with Family Education
Rights and Privacy Act (FERPA) and the Health Insurance
Portability and Accountability Act (HIPAA) prior to receipt
by the study authors. Use of the CDC specifically for the
study described herein was approved by the Simpson
University Institutional Review Board, in accordance
with U.S. Federal regulations.
Study population
As reported by Destefano et al. [14] (CDC) in the ori-
ginal publication, “Children with autism were identified
by the CDC from the Metropolitan Atlanta Develop-
mental Disabilities Surveillance Program (MADDSP), a
multiple-source, population-based surveillance program
that monitors the occurrence of selected developmental
disabilities among children in the 5-county metropol-
itan Atlanta area”. And further, “Autism cases were
identified via screening and abstraction of source files at
schools, hospitals, clinics, and specialty providers”. Of
the cases identified, vaccination records were located
for 660 children. Control children were chosen from
“regular” education programs and were within the same
age group and schools of attendance or neighboring
school as cases. Children missing a vaccination form or
with incomplete vaccination forms (where the forms did
not list at least 1 diphtheria-tetanus-pertusussis vaccine
by 2 years of age or at least 1 MMR vaccine at any age)
were excluded from the study. Children with religious
or medical exemptions were not excluded from the
study. The listed exclusions yielded a cohort size of 624
cases and 1824 controls.
Vaccination histories
Vaccination records were abstracted as described previ-
ously [14] from standardized state immunization forms
that are required for all children who attend school and
early intervention programs in Georgia.
Demographic data
Demographic data including birthdate, gender and race
were obtained for both case and control children via
birth certificates or registration forms kept as a part of
each child’s permanent school record. Georgia state birth
certificate information was used to further obtain each
child’s birthweight. Although actual birthweight data were
not released by the CDC, case and control children were
lumped into birthweight categories: under 1500 grams,
between 1500 and 2500 grams and over 2500 grams. All
individuals less than 3 years of age at the time of testing
(1996) were excluded from the analysis.
Statistical analyses
The Pearson’s chi -squared test contained in the SAS®
software was utilized for current statistical analyses, and
a two-sided p-value < 0.05 was considered statistically
significant. This is in contrast to the original Destefano
et al. [14] (CDC) study, where a case–control study de-
sign was used, where 3 control children were matched
to each case child, and analyzed using conditional logis-
tic regression dichotomized for the three age cut-offs at
18, 24 and 36 months. Pearson’s chi-squared is, in gen-









































Hooker Translational Neurodegeneration 2014, 3:16 Page 2 of 6
http://www.translationalneurodegeneration.com/content/3/1/16
for the present study. However, our results were also
confirmed using a conditional logistic regression design
similar to the Destefano et al. [14] (CDC) study. In the
present study, frequencies of cases were determined
for first MMR ages of less than versus greater than
18 months, 24 months and 36 months in each separate
analysis. When accounting for cases in the cohort that
excluded low birth weight (<2500 g) African American
children, it was necessary to report results at 31 months
rather than 36 months in order to avoid reporting data
from age categories or “cells” that possessed less than 5
individuals.
Results
Table 1 shows the relationship between MMR timing
and autism incidence for the entire cohort. As can be
observed, there is a statistically significant effect for the
cohort at 36 months (RR = 1.49, 95% CI: 1.04-2.14, p =
0.0289). However, this result appears to be caused by a
stronger relationship (RR = 1.69, 95% CI: 1.11-2.57, p =
0.0138) seen exclusively in boys. Girls did not show any
relationship between autism and MMR timing at any
age group studied.
When looking specifically at African American children
(Table 2), the relationship between MMR timing and aut-
ism incidence became more profound (RR = 2.30, 95% CI:
1.25-4.22, p = 0.0060) at 36 months of age. Again, this re-
sult was exclusively found in boys who showed statistically
significant effects at both 24 months (RR = 1.73, 95% CI:
1.09-2.77, p = 0.0200) and 36 months (RR = 3.36, 95% CI:
1.50-7.51, p = 0.0019) of age. This effect again was not
seen in females.
Table 3 shows results for the entire cohort excluding
African American children. As can be observed, there is
no statistically significant effect for any of the subclasses
in either gender or age cut-off for MMR uptake. This
shows that the effect observed overall is due to the very
strong “signal” seen exclusively in African American
boys. In other words, the strong, statistically significant
relationship between younger first MMR age and higher
autism incidence in African American males may be
skewing the results for larger, more general populations
that include African American males (e.g., all boys and
all African Americans) to show a “relationship” that is
actually only in African American males.
Through investigating the cohort demographic data, it
was found that there was a higher proportion of low
birth weight African Americans compared to the entire
cohort, specifically within the portion of the cohort that
possessed a Georgia state birth certificate. The number
of individuals with a birth weight under 2500 g for African
Americans was 11.9% as compared to the total cohort at
8.66%. A final analysis was completed on African Ameri-
can children in the “birth certificate” cohort, excluding
low birth weight individuals (Table 4). Results were ob-
tained at 18 months, 24 months and 31 months, rather
than 36 months, as there were insufficient cases (less than
5) at the 36 month mark to carry out the analysis. Even at
31 months, there were insufficient cases of African Ameri-
can females. Thus, these results are not included in the
analysis. Even excluding low birth weigth individuals, a re-
lationship was seen between first MMR age and autism in-
cidence at 31 months for African American males (RR =
2.64, 95% CI: 1.08-6.46, p = 0.0280).
Discussion
The results show a strong relationship between child age
at the administration of the first MMR and autism
Table 1 Fisher’s exact analysis for the entire cohort
Total cohort Males only Females only
Age cut-off Relative risk 95% CI p-value Relative risk 95% CI p-value Relative risk 95% CI p-value
18 months 1.11 0.91-1.36 0.292 1.21 0.96-1.52 0.102 0.822 0.53-1.27 0.375
24 months 1.21 0.93-1.57 0.151 1.30 0.96-1.76 0.0826 0.936 0.54-1.62 0.812
36 months 1.49* 1.04-2.14 0.0289 1.69* 1.11-2.57 0.0138 0.996 0.49-2.04 0.992
*Result is statistically significant based on p < 0.05.
Table 2 Fisher’s exact analysis for African American children only
Total cohort Males only Females only
Age cut-off Relative risk 95% CI p-value Relative risk 95% CI p-value Relative risk 95% CI p-value
18 months 1.24 0.90-1.70 0.184 1.36 0.95-1.95 0.0880 0.855 0.44-1.68 0.649
24 months 1.47 0.99-2.19 0.0562 1.73* 1.09-2.77 0.0200 0.861 0.40-1.88 0.707
36 months 2.30* 1.25-4.22 0.0060 3.36* 1.50-7.51 0.0019 1.01 0.38-2.68 0.982
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incidence exclusively for African American boys which
could indicate a role of the vaccine in the etiology of
autism within this population group. This particular ana-
lysis was not completed in the original Destefano et al.
[14] (CDC) study. Although the previous study consid-
ered MMR timing and African Americans in general, no
statistically significant effect was observed. This is in
contrast to our result for African Americans in general,
because the CDC study limited the total African American
cohort to include only those individuals who possessed a
valid State of Georgia birth certificate which decreased the
statistical power of their analysis. Although a statistically
significant relationship between first MMR age and autism
incidence was seen in the general (all races) population
within the earlier Destefano et al. [14] study, the coauthors
interpreted this result as an artifact of “healthcare seeking
behavior” citing that autistic children would receive their
vaccines earlier in order to enroll in State of Georgia early
intervention programs. However, it is highly unlikely that
this type of behavior would be seen exclusively in African
American males and thus, alternative hypotheses must be
explored, including the possibility that the MMR vaccine
may be causally linked to autism in African American
males.
It should be noted that a recent publication has shown
that the prevalence of autism in African Americans is
nearly 25% higher than that of whites [15]. This value
was obtained when CDC data were appropriately ana-
lyzed based on socioeconomic status. This could be due
to issues regarding vitamin D status with African Ameri-
cans as it has been estimated that vitamin D sufficiency
among whites is between 30-60% but is only 5-10%
among African Americans [16]. Patrick et al. [17] have
very recently proposed a mechanism for the link between
vitamin D status and autism via selective production of
serotonin in the brain. Disruption of the serotonergic sys-
tem is a very consistent observation with autism [18] as
serotonin promotes prosocial behavior and proper assess-
ment of emotional social cues [19].
Vitamin D has a multitude of other physiological func-
tions in vivo. Vitamin D receptor has been found in
many different tissues including the small intestine,
colon, osteoblasts, activated T and B lymphocytes, islet
cells and most organs in the body [20]. Vitamin D has
also been implicated in many important physiological
processing including modulation of activated T and B
lymphocyte function [21,22] and prevention of inflam-
matory bowel disease [23]. Lower vitamin D status African
American females are more susceptible to lupus [24].
Also, Epstein-Barr Virus antibody titers are significantly
higher in African American youth as compared to com-
pared to white youth [25] which may be a consequence of
vitamin D insufficiency. Also, childhood adversity, which
could be more prevalent in African American boys, can
have lasting immune consequences [26].
Gallagher et al. [27] have reported previously regarding
the Hepatitis B vaccine and autism in neonates, specific-
ally within the 1997 to 2002 time period when this
vaccine series still contained thimerosal. Regarding non-
whites they specifically stated in the abstract, “Non-
white boys bore greater risk” of receiving an autism
diagnosis if they received the Hep B as neonates. The
data reported in this paper show a statistically signifi-
cant risk ratio of 5.53 (p = 0.019) for black boys as op-
posed to white boys who had a risk of 1.87 (p = 0.171)
which was not statistically significant, when looking at
autism in those infants that received their first Hep B
vaccine during the first month of life.
A strength of the current study is that the MADDSP
data were collected independently of the design used in
the analysis. These data were collected as part of the
diagnoses individuals received as part of their participa-
tion in special education program and as such, the
healthcare providers in no way were thinking about the
Table 3 Fisher’s exact analysis excluding African American children
Total cohort Males only Females only
Age cut-off Relative risk 95% CI p-value Relative risk 95% CI p-value Relative risk 95% CI p-value
18 months 1.06 0.81-1.38 0.668 1.17 0.87-1.58 0.309 0.734 0.41-1.31 0.292
24 months 1.06 0.75-1.50 0.745 1.10 0.74-1.62 0.642 0.910 0.41-2.00 0.814
36 months 1.13 0.72-1.78 0.588 1.19 0.72-1.97 0.490 0.835 0.28-2.48 0.745
Table 4 Fisher’s exact analysis for African American children excluding low birth weight
Total cohort Males only Females only
Age cut-off Relative risk 95% CI p-value Relative risk 95% CI p-value Relative risk 95% CI p-value
18 months 0.996 0.66-1.51 0.986 1.06 0.66-1.69 0.819 0.804 0.32-2.00 0.637
24 months 1.29 0.76-2.21 0.348 1.53 0.82-2.85 0.178 0.731 0.25-2.14 0.567
31 months* 1.85 0.91-3.79 0.0872 2.64 1.08-6.46 0.0280 — — —
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potential association between vaccine exposures and
potential health outcomes. Also the current study con-
trolled for a possible association between low birth
weight individuals and autism as in the final analysis on
the African American cohort, all children of birthweight
less than 2500 grams were eliminated from the cohort.
Although low birthweight (LBW) has been shown to be
associated with an increased risk of autism [28], insuffi-
cient information existed within the study population to
assess the effect of LBW on autism incidence or any
interaction between LBW and MMR timing.
The weaknesses of the current study include the age
groups selected for autism cases and controls within the
original data set. The average age to receive an autism
diagnosis has been reported (using the CDC’s Vaccine
Safety Datalink) as between 3.7 [29] and 4.2 years of age
[30]. However, the CDC’s dataset included controls as
young as 3 years of age who could have been “too young”
to receive an autism diagnosis. Accordingly, there is a
greater than 50% probability that some of the controls
could have later received an autism diagnoses, thus skew-
ing the analysis to the null (“no effect”) hypothesis. How-
ever, when the analysis was recompleted using controls
that were six years of age or older, very similar results
were obtained (data not shown). Also, information on the
timing of other infant vaccines was not released by the
CDC and thus it was impossible to control this factor in
the current analysis. In addition, socioeconomic factors
were not assessed in the current analysis. Thus, any differ-
ences in “healthcare seeking behavior” among individuals
vaccinated ontime versus late could not be assessed.
Conclusions
The present study provides new evidence of a statisti-
cally significant relationship between the timing of the
first MMR vaccine and autism incidence in African
American males. Using a straight-forward, Pearson’s chi-
squared analysis on the cohort used in the Destefano
et al. [14] (CDC) study, timing of the first MMR vaccine
before and after 24 months of age and 36 months of age
showed relative risks for autism diagnoses of 1.73 and
3.36, respectively. Future studies should be completed to
further evaluate the relationship of first MMR timing
and neurodevelopmental maladies, including autism, es-
pecially in underserved populations.
Routine childhood vaccination is considered an im-
portant public health tool in reducing the morbidity and
mortality associated with infectious diseases. However,
consideration should be made in the current United
States vaccination schedule for genetic subpopulations
that may be associated with vaccine adverse events. Add-
itional research is required to better understand the rela-
tionship between MMR exposure and autism in African
American males.
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